Immunoexpression of tumor suppressor genes p53, p21WAF1/CIP1 and p27KIP1 in human astrocytic tumors

Arquivos de Neuro-Psiquiatria

Volumn 65, Issue 4 B, 2007, Pages 1114-1122

  Faria, Mário Henrique Girão ^a,b,c   Do Patrocínio, Régia Maria Do Socorro Vidal ^a   De Moraes Filho, Manoel Odorico ^a,b   Rabenhorst, Silvia Helena Barem ^a,b  

^a FEDERAL UNIVERSITY OF CEARÁ   (Brazil)

^b UFC

^c Pesquisas e Serviços Ltda ^*  (Brazil)

Author keywords

Astrocytoma; Glioblastoma; Immunohistochemistry; Tumor suppressor genes

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 1; CYCLIN DEPENDENT KINASE INHIBITOR 1B; PROTEIN P53;

ARTICLE; ASTROCYTOMA; CANCER GROWTH; CONTROLLED STUDY; GENE EXPRESSION; GENE MUTATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALIGNANT TRANSFORMATION; PROTEIN EXPRESSION; TUMOR SUPPRESSOR GENE;

EID: 41549156384     PISSN: 0004282X     EISSN: 16784227     Source Type: Journal    
DOI: 10.1590/S0004-282X2007000700004     Document Type: Article

References (45)

1. CBTRUS. Statistical report: primary brain tumours in the United States (1998-2002). Chicago: Central Brain Tumor Registry of the United States, 2005:9-50.
2. Louis DN, Ohgaki H, Wiestler OD, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol (Berl) 2007;114:97-109.
3. Reifenberger G, Collins VP. Pathology and molecular genetics of astrocytic gliomas. J Mol Med 2004;82:656-670.
4. Giacinti C, Giordano A. RB and cell cycle progression. Oncogene 2006;25:5220-5227.
5. Louis DN, von Deimling A, Chung RY, et al. Comparative study of p53 gene and protein alterations in human astrocytic tumors. J Neuropathol Exp Neurol 1993;52:31-38.
6. Strano S, Dell'Orso S, Di Agostino S, et al. Mutant p53: an oncogenic transcription factor. Oncogene 2007;26:2212-2219.
7. Isolan GR, Ribas JM Filho, Isolan PM, et al. Astrocytic neoplasms and correlation with mutate p53 and Ki-67 proteins. Arq Neuropsiquiatr 2005;63:997-1004.
8. Ono Y, Tamiya T, Ichikawa T, et al. Accumulation of wild-type p53 in astrocytomas is associated with increased p21 expression. Acta Neuropathol (Berl) 1997;94:21-27.
9. Lloyd RV, Erickson LA, Jin L, et al. p27kip1: a multifunctional cyclin-dependent kinase inhibitor with prognostic significance in human cancers. Am J Pathol 1999;154:313-323.
10. Coqueret O. New roles for p21 and p27 cell-cycle inhibitors: a function for each cell compartment? Trends Cell Biol 2003;13:65-70.
11. Bloom J, Pagano M. Deregulated degradation of the cdk inhibitor p27 and malignant transformation. Semin Cancer Biol 2003;13:41-47.
12. Faria MH, Goncalves BP, Patrocinio RM, Moraes-Filho MO, Rabenhorst SH. Expression of Ki-67, topoisomerase IIalpha and c-MYC in astrocytic tumors: correlation with the histopathological grade and proliferative status. Neuropathology 2006;26:519-527.
13. Landberg G, Roos G. Proliferating cell nuclear antigen and Ki-67 antigen expression in human haematopoietic cells during growth stimulation and differentiation. Cell Prolif 1993;26:427-437.
14. McCarty KS Jr, Miller LS, Cox EB, Konrath J, McCarty KS Sr. Estrogen receptor analyses. Correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies. Arch Pathol Lab Med 1985;109:716-721.
15. Jaros E, Perry RH, Adam L, et al. Prognostic implications of p53 protein, epidermal growth factor receptor, and Ki-67 labelling in brain tumours. Br J Cancer 1992;66:373-385.
16. Lang FF, Miller DC, Koslow M, Newcomb EW. Pathways leading to glioblastoma multiforme: a molecular analysis of genetic alterations in 65 astrocytic tumors. J Neurosurg 1994;81:427-436.
17. Kordek R, Biernat W, Debiec-Rychter M, Alwasiak J, Liberski PP. Comparative evaluation of p53-protein expression and the PCNA and Ki-67 proliferating cell indices in human astrocytomas. Pathol Res Pract 1996;192:205-209.
18. Khalid MH, Yagi N, Hiura T, Shibata S. Immunohistochemical analysis of p53 and p21 in human primary glioblastomas in relation to proliferative potential and apoptosis. Brain Tumor Pathol 1998;15:89-94.
19. Kirla R, Salminen E, Huhtala S, et al. Prognostic value of the expression of tumor suppressor genes p53, p21, p16 and prb, and Ki-67 labelling in high grade astrocytomas treated with radiotherapy. J Neurooncol 2000;46:71-80.
20. Pardo FS, Hsu DW, Zeheb R, et al. Mutant, wild type, or overall p53 expression: freedom from clinical progression in tumours of astrocytic lineage. Br J Cancer 2004;91:1678-1686.
21. Nayak A, Ralte AM, Sharma MC, et al. p53 protein alterations in adult astrocytic tumors and oligodendrogliomas. Neurol India 2004;52:228-232.
22. Mashiyama S, Murakami Y, Yoshimoto T, Sekiya T, Hayashi K. Detection of p53 gene mutations in human brain tumors by single-strand conformation polymorphism analysis of polymerase chain reaction products. Oncogene 1991;6:1313-1318.
23. Fults D, Brockmeyer D, Tullous MW, Pedone CA, Cawthon RM. p53 mutation and loss of heterozygosity on chromosomes 17 and 10 during human astrocytoma progression. Cancer Res 1992;52:674-679.
24. Wu JK, Ye Z, Darras BT. Frequency of p53 tumor suppressor gene mutations in human primary brain tumors. Neurosurgery 1993;33:824-830.
25. Chozick BS, Pezzullo JC, Epstein MH, Finch PW. Prognostic implications of p53 overexpression in supratentorial astrocytic tumors. Neurosurgery 1994;35:831-837.
26. Rasheed BK, McLendon RE, Herndon JE, et al. Alterations of the TP53 gene in human gliomas. Cancer Res 1994;54:1324-1330.
27. Patt S, Gries H, Giraldo M et al. p53 gene mutations in human astrocytic brain tumors including pilocytic astrocytomas. Hum Pathol 1996;27: 586-589.
28. Hayes VM, Dirven CM, Dam A, et al. High frequency of TP53 mutations in juvenile pilocytic astrocytomas indicates role of TP53 in the development of these tumors. Brain Pathol 1999;9:463-467.
29. Kato H, Kato S, Kumabe T et al. Functional evaluation of p53 and PTEN gene mutations in gliomas. Clin Cancer Res 2000;6:3937-3943.
30. Birner P, Piribauer M, Fischer I et al. Prognostic relevance of p53 protein expression in glioblastoma. Oncol Rep 2002;9:703-707.
31. Tsuchiya K. Functional restoration of tumor suppressor p53 alters susceptibility of glioblastoma cells to irradiation-analysis using a cell line containing a temperature-sensitive mutant. Hokkaido Igaku Zasshi 2000;75:265-274.
32. Geoerger B, Vassal G, Opolon P, et al. Oncolytic activity of p53-expressing conditionally replicative adenovirus AdDelta24-p53 against human malignant glioma. Cancer Res 2004;64:5753-5759.
33. Johnson M, Dimitrov D, Vojta PJ, et al. Evidence for a p53-independent pathway for upregulation of SDI1/CIP1/WAF1/p21 RNA in human cells. Mol Carcinog 1994;11:59-64.
34. Jung JM, Li H, Kobayashi T, et al. Inhibition of human glioblastoma cell growth by WAF1/Cip1 can be attenuated by mutant p53. Cell Growth Differ 1995;6:909-913.
35. Piva R, Cavalla P, Bortolotto S et al. p27/kip1 expression in human astrocytic gliomas. Neurosci Lett 1997;234:127-130.
36. Mizumatsu S, Tamiya T, Ono Y, et al. Expression of cell cycle regulator p27Kip1 is correlated with survival of patients with astrocytoma. Clin Cancer Res 1999;5:551-557.
37. Alleyne CH Jr, He J, Yang J et al. Analysis of cyclin dependent kinase inhibitors in malignant astrocytomas. Int J Oncol 1999;14:1111-1116.
38. Zagzag D, Blanco C, Friedlander DR, Miller DC, Newcomb EW. Expression of p27KIP1 in human gliomas: relationship between tumor grade, proliferation index, and patient survival. Hum Pathol 2003;34:48-53.
39. Kirla RM, Haapasalo HK, Kalimo H, Salminen EK. Low expression of p27 indicates a poor prognosis in patients with high-grade astrocytomas. Cancer 2003;97:644-648.
40. Chen J, Willingham T, Shuford M, Nisen PD. Tumor suppression and inhibition of aneuploid cell accumulation in human brain tumor cells by ectopic overexpression of the cyclin-dependent kinase inhibitor p27KIP1. J Clin Invest 1996;97:1983-1988.
41. Park KH, Lee J, Yoo CG, et al. Application of p27 gene therapy for human malignant glioma potentiated by using mutant p27. J Neurosurg 2004;101:505-510.
42. Hochhauser D. Modulation of chemosensitivity through altered expression of cell cycle regulatory genes in cancer. Anticancer Drugs 1997;8:903-910.
43. Saito N, Yamamoto T, Watanabe T, Abe Y, Kumagai T. Implications of p53 protein expression in experimental spinal cord injury. J Neurotrauma 2000;17:173-182.
44. Korshunov A, Golanov A, Sycheva R. Immunohistochemical markers for prognosis of cerebral glioblastomas. J Neurooncol 2002;58:217-236.
45. Graeber MB, Scheithauer BW, Kreutzberg GW. Microglia in brain tumors. Glia 2002;40:252-259.